AmCad BioMed Corporation (TPEX:4188)

AmCad BioMed Statistics

Total Valuation

AmCad BioMed has a market cap or net worth of TWD 706.16 million. The enterprise value is 442.09 million.

Market Cap	706.16M
Enterprise Value	442.09M

Important Dates

The next estimated earnings date is Friday, August 7, 2026.

Earnings Date	Aug 7, 2026
Ex-Dividend Date	n/a

Share Statistics

AmCad BioMed has 63.33 million shares outstanding. The number of shares has increased by 6.46% in one year.

Current Share Class	63.33M
Shares Outstanding	63.33M
Shares Change (YoY)	+6.46%
Shares Change (QoQ)	+1.62%
Owned by Insiders (%)	6.64%
Owned by Institutions (%)	0.95%
Float	31.63M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.50
PB Ratio	1.22
P/TBV Ratio	1.59
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-8.24
EV / Sales	14.71
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.38

Financial Position

The company has a current ratio of 23.23, with a Debt / Equity ratio of 0.03.

Current Ratio	23.23
Quick Ratio	21.42
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.31
Interest Coverage	-751.88

Financial Efficiency

Return on equity (ROE) is -11.22% and return on invested capital (ROIC) is -8.55%.

Return on Equity (ROE)	-11.22%
Return on Assets (ROA)	-8.37%
Return on Invested Capital (ROIC)	-8.55%
Return on Capital Employed (ROCE)	-14.42%
Weighted Average Cost of Capital (WACC)	5.92%
Revenue Per Employee	883,647
Profits Per Employee	-1.58M
Employee Count	34
Asset Turnover	0.05
Inventory Turnover	0.67

Taxes

Income Tax	-15,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.17% in the last 52 weeks. The beta is 0.32, so AmCad BioMed's price volatility has been lower than the market average.

Beta (5Y)	0.32
52-Week Price Change	-25.17%
50-Day Moving Average	12.00
200-Day Moving Average	14.27
Relative Strength Index (RSI)	33.41
Average Volume (20 Days)	45,085

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AmCad BioMed had revenue of TWD 30.04 million and -53.66 million in losses. Loss per share was -0.84.

Revenue	30.04M
Gross Profit	10.74M
Operating Income	-84.96M
Pretax Income	-68.36M
Net Income	-53.66M
EBITDA	-74.38M
EBIT	-84.96M
Loss Per Share	-0.84

Balance Sheet

The company has 355.19 million in cash and 14.50 million in debt, with a net cash position of 340.69 million or 5.38 per share.

Cash & Cash Equivalents	355.19M
Total Debt	14.50M
Net Cash	340.69M
Net Cash Per Share	5.38
Equity (Book Value)	579.14M
Book Value Per Share	7.81
Working Capital	375.04M

Cash Flow

In the last 12 months, operating cash flow was -46.91 million and capital expenditures -201,000, giving a free cash flow of -47.11 million.

Operating Cash Flow	-46.91M
Capital Expenditures	-201,000
Depreciation & Amortization	10.58M
Net Borrowing	-4.91M
Free Cash Flow	-47.11M
FCF Per Share	-0.74

Margins

Gross margin is 35.73%, with operating and profit margins of -282.80% and -178.59%.

Gross Margin	35.73%
Operating Margin	-282.80%
Pretax Margin	-227.55%
Profit Margin	-178.59%
EBITDA Margin	-247.57%
EBIT Margin	-282.80%
FCF Margin	n/a

Dividends & Yields

AmCad BioMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.46%
Shareholder Yield	-6.46%
Earnings Yield	-7.60%
FCF Yield	-6.67%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1